Insulin Efsitora Alfa

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

DiabetesT2DType 1 DiabetesType 2 DiabetesType 2 Diabetes Treated With Insulin

Phase 3

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

CompletedNCT05275400

Eli Lilly and CompanyType 2 Diabetes

Start: 2022-03-08End: 2024-05-15Updated: 2025-06-03

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

CompletedNCT05362058

Eli Lilly and CompanyDiabetes, Type 2 Diabetes

Start: 2022-06-03End: 2024-04-10Updated: 2025-05-16

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

CompletedNCT05462756

Eli Lilly and CompanyType 2 Diabetes, Type 2 Diabetes Treated With Insulin

Start: 2022-08-11End: 2024-02-27Updated: 2025-04-27

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

CompletedNCT05463744

Eli Lilly and CompanyDiabetes, Type 1 Diabetes

Start: 2022-08-12End: 2024-05-07Updated: 2025-06-24

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

CompletedNCT05662332

Eli Lilly and CompanyT2D, Type 2 Diabetes

Start: 2023-01-14End: 2024-07-19Updated: 2025-08-06

Related Papers

Evaluation of Overall Health State, Treatment Burden, and Satisfaction with Insulin Efsitora Alfa (Efsitora) vs. Daily Comparator in Adults with Type 2 Diabetes in the QWINT Clinical Trial Program.

2026-01-27

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy

New England Journal of Medicine2025-06-2213 citations

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.

2025-06-229 citations

Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.

2025-06-228 citations

810-P: Insulin Efsitora Alfa vs. Insulin Degludec in Adults with Insulin-Naïve T2D (QWINT-2)—A Japan Subgroup Analysis

Diabetes2025-06-13

Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes

Diabetes Therapy2025-02-102 citations

Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment

New England Journal of Medicine2024-09-1040 citations

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.

2024-09-1026 citations